Extracellular Vesicles and Biomaterial ...
Type de document :
Article dans une revue scientifique: Article de synthèse/Review paper
PMID :
URL permanente :
Titre :
Extracellular Vesicles and Biomaterial Design: New Therapies for Cardiac Repair.
Auteur(s) :
Pezzana, Chloé [Auteur]
Paris-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)]
Agnely, Florence [Auteur]
Institut Galien Paris-Sud [IGPS]
Bochot, Amélie [Auteur]
Institut Galien Paris-Sud [IGPS]
Siepmann, Juergen [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Menasché, Philippe [Auteur]
Paris-Centre de Recherche Cardiovasculaire [PARCC - UMR-S U970]
Paris-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)]
Agnely, Florence [Auteur]
Institut Galien Paris-Sud [IGPS]
Bochot, Amélie [Auteur]
Institut Galien Paris-Sud [IGPS]
Siepmann, Juergen [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Menasché, Philippe [Auteur]
Paris-Centre de Recherche Cardiovasculaire [PARCC - UMR-S U970]
Titre de la revue :
Trends in Molecular Medicine
Nom court de la revue :
Trends Mol Med
Numéro :
27
Pagination :
231-247
Date de publication :
2020-11-29
ISSN :
1471-499X
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The use of extracellular vesicles (EVs) for cardiac regenerative medicine as an alternative to cell transplantation has been demonstrated.
For clinical applications, new translational issues have emerged such as ...
Lire la suite >The use of extracellular vesicles (EVs) for cardiac regenerative medicine as an alternative to cell transplantation has been demonstrated. For clinical applications, new translational issues have emerged such as parental cell selection, large-scale production, characterization, and delivery. Two main delivery approaches of EVs for heart repair can be used: either direct myocardial delivery in patients requiring surgery, or intravenous (IV) infusion. To potentiate EV beneficial effects, direct myocardial EV administration can be optimized by controlled-release biomaterials, whereas EV engineering should allow IV-injected EVs to be directed more specifically to the heart. However, new challenges include possible changes in EV bioactivity because of their interactions with the biomaterial, as well as the complexities of EV engineering to improve organ-specific targeting. There is increasing evidence that extracellular vesicles (EVs) mediate the paracrine effects of stem cells. Although EVs have several attractive characteristics, they also raise issues related to delivery. For patients with cardiac disease that require a surgical procedure, direct intramyocardial (IM) administration of EVs is straightforward but its efficacy may be limited by fast wash-out, hence the interest of incorporating EVs into a controlled release polymer to optimize their residence time. For patients without surgical indication, the intravenous (IV) route is attractive because of its lack of invasiveness; however, whole-body distribution limits the fraction of EVs that reach the heart, hence the likely benefits of EV engineering to increase EV homing to the target tissue.Lire moins >
Lire la suite >The use of extracellular vesicles (EVs) for cardiac regenerative medicine as an alternative to cell transplantation has been demonstrated. For clinical applications, new translational issues have emerged such as parental cell selection, large-scale production, characterization, and delivery. Two main delivery approaches of EVs for heart repair can be used: either direct myocardial delivery in patients requiring surgery, or intravenous (IV) infusion. To potentiate EV beneficial effects, direct myocardial EV administration can be optimized by controlled-release biomaterials, whereas EV engineering should allow IV-injected EVs to be directed more specifically to the heart. However, new challenges include possible changes in EV bioactivity because of their interactions with the biomaterial, as well as the complexities of EV engineering to improve organ-specific targeting. There is increasing evidence that extracellular vesicles (EVs) mediate the paracrine effects of stem cells. Although EVs have several attractive characteristics, they also raise issues related to delivery. For patients with cardiac disease that require a surgical procedure, direct intramyocardial (IM) administration of EVs is straightforward but its efficacy may be limited by fast wash-out, hence the interest of incorporating EVs into a controlled release polymer to optimize their residence time. For patients without surgical indication, the intravenous (IV) route is attractive because of its lack of invasiveness; however, whole-body distribution limits the fraction of EVs that reach the heart, hence the likely benefits of EV engineering to increase EV homing to the target tissue.Lire moins >
Langue :
Anglais
Audience :
Internationale
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Date de dépôt :
2022-12-08T01:35:31Z
2023-03-01T07:20:51Z
2023-03-01T07:20:51Z